WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammatory Research

Executive Summary: WY-14643 (Pirinixic Acid) is a highly selective peroxisome proliferator-activated receptor alpha (PPARα) agonist (IC₅₀ = 10.11 µM, human PPARα) that modulates lipid metabolism and inflammation in cellular and animal models (APExBIO). The compound's aliphatic α-substitution enhances dual PPARα/γ agonism, supporting balanced metabolic interventions (Bao et al., 2025). WY-14643 down-regulates VCAM-1 in endothelial cells, reducing monocyte adhesion and TNF-α–induced inflammation. In high-fat-fed rat models, 3 mg/kg/day oral dosing for 2 weeks improves insulin sensitivity, lowers plasma glucose and triglycerides, and reduces visceral fat without increasing body mass. The compound is insoluble in water but highly soluble in DMSO and ethanol, and is stable under -20°C storage. All claims are supported by peer-reviewed and product documentation.

Biological Rationale

WY-14643 (Pirinixic Acid) is designed as a potent and selective PPARα agonist. PPARα is a ligand-activated nuclear receptor that regulates genes involved in lipid metabolism, fatty acid oxidation, and inflammatory responses (Bao et al., 2025). Activating PPARα increases hepatic fatty acid oxidation, reduces triglyceride synthesis, and attenuates pro-inflammatory signaling. Genetic and proteomic evidence demonstrates that PPARα signaling mediates metabolic homeostasis and modulates tumor microenvironments in select cancer types. WY-14643 also exhibits partial agonist activity for PPARγ when α-substituted, enabling dual modulation of lipid and glucose metabolism (APExBIO).

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds the ligand-binding domain of human PPARα with an IC₅₀ of 10.11 µM, inducing conformational changes that promote coactivator recruitment and target gene transcription. Upon PPARα activation, expression of genes involved in β-oxidation (e.g., CPT1A, ACOX1) increases, while inflammatory mediators such as VCAM-1 and TNF-α–responsive elements are down-regulated (Bao et al., 2025). In Kupffer cells, WY-14643 moderately elevates hepatic TNFα mRNA, indirectly stimulating hepatocyte mitogenesis. When α-substituted, the compound achieves balanced dual agonism for PPARα/γ, with effective concentrations in the lower micromolar range. Cellular studies show that pretreatment with 250 μM WY-14643 significantly down-regulates VCAM-1 expression and reduces monocyte adhesion, indicating anti-inflammatory effects (APExBIO).

Evidence & Benchmarks

• WY-14643 demonstrates high selectivity for human PPARα, with an IC₅₀ of 10.11 µM (in vitro receptor binding; APExBIO).
• Aliphatic α-substitution enhances dual PPARα/γ agonism, supporting metabolic and anti-inflammatory activity (structure-activity relationship; Bao et al., 2025).
• WY-14643 at 250 μM significantly suppresses TNF-α–induced VCAM-1 expression and monocyte adhesion in endothelial cells (cell-based assay; Bao et al., 2025).
• In high-fat-fed rat models, oral administration at 3 mg/kg/day for 2 weeks lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, reduces visceral fat, and enhances insulin sensitivity (animal study; Bao et al., 2025).
• WY-14643 indirectly upregulates hepatic TNFα mRNA via Kupffer cells, promoting hepatocyte proliferation (liver tissue analysis; Bao et al., 2025).
• Compound is insoluble in water but soluble in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL, ultrasonic assistance); stable at -20°C (material stability data; APExBIO).
• Recent tumor microenvironment studies implicate PPARα signaling, modulated by WY-14643, in regulating tissue factor (TF) expression and leukocyte migration in rare lung cancer (Bao et al., 2025).

This article extends previous discussions by integrating new evidence from multiomics cancer models, highlighting WY-14643's unique role in both metabolic and tumor microenvironment research. For a mechanistic and translational roadmap, see this strategic guide; our article adds direct protocol benchmarks and data integration.

Applications, Limits & Misconceptions

WY-14643 is widely used in metabolic disorder modeling, lipid metabolism studies, inflammation research, and as a tool to dissect PPAR signaling in translational pipelines. It is not approved for clinical, diagnostic, or therapeutic use in humans. The compound is recommended for short-term solution use, with storage at -20°C. APExBIO supplies the A4305 kit for research purposes, ensuring reagent quality and batch traceability (APExBIO).

Common Pitfalls or Misconceptions

• Not a clinical drug: WY-14643 is for research use only; not approved for clinical or diagnostic purposes (APExBIO).
• Solubility constraints: Compound is insoluble in water; improper dissolution may lead to inconsistent assay results.
• Short-term solution stability: Stock solutions in DMSO or ethanol should be freshly prepared and used shortly to avoid degradation.
• Model-specific effects: Efficacy and cellular responses may vary between cell types and animal models; dose titration is needed for optimal outcomes (Bao et al., 2025).
• No effect in PPARα knockout systems: WY-14643 requires functional PPARα for activity; use of knockout models will abrogate effects.

For a comparison of mechanistic insights and translational strategies, see this review, which our article updates with direct product benchmarks and protocol recommendations.

Workflow Integration & Parameters

For in vitro use, dissolve WY-14643 in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL with ultrasonic assistance). Use at working concentrations of 10–250 μM, adjusting according to cell line sensitivity and experimental goals. In animal studies, oral administration of 3 mg/kg/day for 14 days is validated for metabolic readouts in high-fat-fed rats. Solutions should be prepared fresh or stored at -20°C for short-term use. Ensure appropriate vehicle controls and titrate doses in new model systems. Detailed troubleshooting and translational workflow guidance are available in the benchmarking article; here, we focus on solution chemistry and validated dosing regimens.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) is a validated, highly selective PPARα agonist with proven activity in metabolic, inflammatory, and tumor microenvironment research. By modulating key pathways in lipid metabolism and inflammation, it serves as a critical tool for dissecting the PPAR signaling axis and developing new models of disease. APExBIO remains a leading supplier of research-grade WY-14643, supporting innovation in metabolic disorder and oncology pipelines. Ongoing studies continue to expand the translational utility of this compound across preclinical settings (Bao et al., 2025).